Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma
Background: R-CHOP/R-CVP is the only recommended first-line treatment for Non-Hodgkin's Lymphoma (NHL). Limited treatment alternatives often lead to relapse and refractory NHL, which increases disease progressivity and worsens prognosis. Bendamustine-rituximab is being studied for its potential...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Livro |
| Publicado em: |
Interna Publishing,
2022-04-01T00:00:00Z.
|
| Assuntos: | |
| Acesso em linha: | Connect to this object online. |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Área/Cota: |
A1234.567 |
|---|---|
| Cód. Barras: 1 | Disponível |